• Publications
  • Influence
Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).
CONTEXT The Heart and Estrogen/progestin Replacement Study (HERS) found no overall reduction in risk of coronary heart disease (CHD) events among postmenopausal women with CHD. However, in theExpand
  • 1,802
  • 36
  • PDF
Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.
CONTEXT Orlistat, a gastrointestinal lipase inhibitor that reduces dietary fat absorption by approximately 30%, may promote weight loss and reduce cardiovascular risk factors. OBJECTIVE To test theExpand
  • 859
  • 32
Lipoprotein Management in Patients With Cardiometabolic Risk
Risk factors for type 2 diabetes and cardiovascular disease (CVD) often cluster, including obesity (particularly central), insulin resistance, hyperglycemia, dyslipoproteinemia, and hypertension.Expand
  • 751
  • 30
  • PDF
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter trial was to compare rosuvastatin with atorvastatin, pravastatin, and simvastatin across dose ranges forExpand
  • 1,299
  • 29
  • PDF
Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.
This article summarizes the final conclusions of the National Lipid Association (NLA) Statin Safety Task Force, based on a review and independent research of New Drug Application (NDA) information,Expand
  • 412
  • 23
  • PDF
Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation.
Risk factors for type 2 diabetes and cardiovascular disease (CVD) often cluster, including obesity (particularly central), insulin resistance, hyperglycemia, dyslipoproteinemia, and hypertension.Expand
  • 504
  • 22
  • PDF
Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives.
The most common omega-3 fatty acids contain 18-22 carbons and a signature double bond at the third position from the methyl (or n, or omega) end of the molecule. These fatty acids must be obtained inExpand
  • 514
  • 20
  • PDF
Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids.
  • M. Davidson
  • Medicine
  • The American journal of cardiology
  • 21 August 2006
A mechanism to explain the hypotriglyceridemic effects of marine omega-3 fatty acids in humans has not been clarified. A working model can be developed at the gene transcriptional level, whichExpand
  • 341
  • 20
Diagnosis and treatment of familial hypercholesterolaemia.
Familial hypercholesterolaemia (FH) is an autosomal dominant genetic disorder, associated with elevated levels of low-density lipoprotein-cholesterol (LDL-C), which can lead to prematureExpand
  • 201
  • 18
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.
CONTEXT Carotid artery intima-media thickness (CIMT) is a marker of coronary atherosclerosis and independently predicts cardiovascular events, which are increased in type 2 diabetes mellitus (DM).Expand
  • 625
  • 17
  • PDF
...
1
2
3
4
5
...